ClinicalTrials.gg
TerminatedNCT05024708CA2VDUpdated Oct 15, 2026

Athlete's Heart or Arrhythmogenic Right Ventricular Cardiomyopathy: Contribution of Exercise Cardiovascular Magnetic Resonance (CMR)

An interventional study of Cardiac exercises and tests in Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by Rennes University Hospital. Terminated at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
Inclusions were in February 2024, following the replacement of the MRI scanner in which the stress-induction system had been installed. To date, technical tests were conducted but failed to establish a reliable system.
Updated Oct 15, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prospective, nonrandomized, single-center, comparative study to define if right ventricular (RV) contractile reserve assessed by exercise CMR helps to improve the differential diagnosis between pathological and physiological remodeling of the RV; ie. arrhythmogenic right ventricular cardiomyopathy (ARVC) and athlete's heart.

Read the detailed description

Comparison of the RV contractile reserve in 4 groups of patients: Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients; endurance athletes with a dilated RV, endurance athletes with normal RV, untrained subject with normal RV.

Patients will come to the hospital for 3 visits (3 half days):

  • Visit 1: clinical evaluation, rest ECG, rest echocardiography, cardio-pulmonary exercise test.
  • Visit 2: exercise echocardiography, holter ECG monitor (48 yours)
  • Visit 3: rest CMR and exercise CMR (ergocycle)
02

Conditions studied

  • Arrhythmogenic Right Ventricular Cardiomyopathy

Keywords

  • ARVC, Athlete's heart, exercise, CMR, RV contractile reserve
03

In context

Arrhythmogenic Right Ventricular Dysplasia

49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.

This study's enrollment of 4 is below the median of 22 across 15 interventional studies indexed under Arrhythmogenic Right Ventricular Dysplasia.

Browse Arrhythmogenic Right Ventricular Dysplasia studies →

Lead sponsor

Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years and older,

    • patients with confirmed ARVC, but with no major RV dysfunction (RVEF >40%)
    • endurance athletes with dilated RV
    • endurance athletes with non-dilated RV
    • untrained healthy subjects with non-dilated RV
  • who signed a written free and :

Exclusion criteria

Exclusion Criteria:

  • Patients with other cardiovascular disease;
  • to CMR (in particular presence of a non-CMR compatible implantable cardiac defibrillator);
  • Patients with permanent supraventricular arrhythmia;
  • Patients unable to perform an exercise test on an ergocycle;
  • Person subject to legal protection (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    ARVC patients

    Other: Cardiac exercises and tests

  • Active comparator
    Endurance athletes with a dilated RV

    Other: Cardiac exercises and tests

  • Active comparator
    Endurance athletes with normal RV

    Other: Cardiac exercises and tests

  • Experimental
    Untrained subject with normal RV

    Other: Cardiac exercises and tests

Interventions

  • OtherCardiac exercises and tests

    Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)

06

What researchers measure

Primary outcomes

  1. Evolution of right ventricular ejection fraction (RVEF) assessed with CMR during exercise

    Time frame: Through study completion, an average of 1 month

Secondary outcomes

  1. Evolution of Tricuspid annular plane systolic excursion (TAPSE) during exercise

    Time frame: Through study completion, an average of 1 month

  2. Evolution of S' tricuspid wave during exercise

    Time frame: Through study completion, an average of 1 month

  3. Evolution of RV fractional area during exercise

    Time frame: Through study completion, an average of 1 month

  4. Evolution of free wall RV strain during exercise

    Time frame: Through study completion, an average of 1 month

07

Study locations

1 site
  • CHU Rennes
    Rennes, 35033, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2023 to primary completion in Mar 2026, 37 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2024 → Mar 2026 and completion Jan 2024 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Aug 27, 2021
StartActual
Jan 16, 2023
Primary completionActual
Mar 5, 2026was Jan 2024
CompletionActual
Mar 5, 2026was Jan 2024
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Inclusions were in February 2024, following the replacement of the MRI scanner in which the stress-induction system had been installed. To date, technical tests were conducted but failed to establish a reliable system.
changed Oct 15, 2026
Primary completion
Jan 16, 2024→Mar 5, 2026 (actual)
Oct 15, 2026
Study completion
Jan 16, 2024→Mar 5, 2026 (actual)
Oct 15, 2026
Enrollment
60 (estimated)→4 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Status unknown→Terminated
    Why stopped Inclusions were in February 2024, following the replacement of the MRI scanner in which the stress-induction system had been installed. To date, technical tests were conducted but failed to establish a reliable system.
    Primary completion Jan 16, 2024→Mar 5, 2026 (now actual)
    Study completion Jan 16, 2024→Mar 5, 2026 (now actual)
    Enrollment 60 (estimated)→4 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05024708
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Jan 16, 2023
Primary completion
Mar 5, 2026
Completion
Mar 5, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion